Nuclear Medicine Market Report Up to 2031: Visiongain

Visiongain has published a new report on Nuclear Medicine Market Report 2021-2031: Forecasts by Type (Diagnostic (SPECT - Technetium, PET- F-18), by Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology). PLUS, Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS, COVID-19 Recovery Scenarios.

Nuclear medicine/ radio-pharmaceuticals are radioactive compounds administered to the patient and monitored via specific imaging devices for diagnosis and therapeutic purposes.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/nuclear-medicine-market-2021/#download_sampe_div

A radio-pharmaceutical is a drug that can be used either for diagnostic or therapeutic purposes. It is made of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues, or cells.

Radioisotopes emitting short-range particles are used for therapy due to their power to lose all their energy over a very short range. This property is used for therapeutic purposes like cancer cells destruction pain treatment in palliative care for bone cancer or arthritis. Such isotopes stay longer in the body than imaging ones, this is intentional in order to increase treatment efficiency.

COVID-19 Impact on Nuclear Medicine/Radio-pharmaceuticals market

Nuclear medicines/ radio-pharmaceutical markets are likely to grow because of the pandemic Covid 19.

Because of the pandemic hospitals are running with the overcapacity. Threat is driving to the patients having heart disease and cancers patients, hence the patients are likely to be diverted towards nuclear medicine/ radio-pharmaceuticals.

Market Drivers

Growth in the market can be divided into factors such as increasing incidence and happening of cancer and cardiac problems.

Market Restraints

Radio-pharmaceuticals reduces their potential adoption as hospital budget cuts and high equipment prices are expected to limit market growth to certain point.

Get Detailed TOC @ https://www.visiongain.com/report/nuclear-medicine-market-2021/#download_sampe_div

Market Opportunities

Use of Radio-pharmaceuticals in Neurological Applications is paving the way for the nuclear medicines market towards growth.

Competitive Landscape

The nuclear medicine market is working towards the development of novel technologies for radioisotopes production government funding and company initiatives in the respected country.Major companies in the production of nuclear medicines include: Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), NTP Radioisotopes (South Africa), JSC Isotope (Russia), NorthStar Medical Radioisotopes (US), Eckert & Ziegler (Germany), Jubilant DraxImage (Canada), PharmaLogic (US), Institute of Isotopes Co., Ltd. (Hungary), Sinotau Pharmaceuticals (China), Isotopia Molecular Imaging Limited (Israel), SHINE Medical Technologies (US), and Global Medical Solutions (US).

Recent Developments

In 2019. Curium acquired MAP Medical, which will help it to upsurge its geographical presence in Europe with direct access to Nordic and Baltic countries.
In 2019, Eczacýbaþý-Monrol and Telix Pharmaceuticals Limited (Australia) signed a manufacturing and distribution contract. According to the contract signed, Eczacýbaþý-Monrolwill work as a radiopharmaceutical production partner and distributor in Turkey, the Middle East, and North Africa for Telix.
In 2019, Curium (France) and NRG (Netherlands) signed a contract for the production of Molybdenum-99.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Nuclear Medicine market and leading companies. You will find data, trends and predictions.

Find more Visiongain research reports on Pharma New Technologies; click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:

Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter

SOURCE Visiongain Limited.

Nuclear Medicine Market Report Up to 2031: Visiongain Research Inc

Mot-clé